Startups & FundingLOT 261119 · 3 min read

MegaRobo Raises Nearly $200 Million for AI-Run Robotic Laboratories

Suzhou-based MegaRobo raised nearly $200 million with backing from Oman's sovereign wealth fund. Total funding reaches about $600 million as it builds AI-run robotic laboratories for drug discovery.

By Sophie Lindqvist587 words

Key takeaways

  1. MegaRobo raised nearly $200 million in a round joined by Oman Investment Authority, announced Nov. 18.
  2. SiliconANGLE estimates total funding at about $600 million, including a Series C of nearly $300 million in 2022.
  3. The company claims more than 500 product customers and over 200 Megalaxy Lab users, without naming any.
  4. Poreva Open, with Tencent Cloud and Twist Bioscience, will test more than 10,000 submitted protein sequences.
  5. No valuation or lead investor was disclosed.
MegaRobo raises nearly $200 million from Oman's wealth fund and others for AI-run robotic labs
MegaRobo raises nearly $200 million from Oman's wealth fund and others for AI-run robotic labs — DarkoStojanovic / pixabay

MegaRobo has raised nearly $200 million in a round joined by the Oman Investment Authority, the sultanate's sovereign wealth fund. The Suzhou-based company builds automated laboratories in which AI software designs and runs real experiments. It announced the round on Nov. 18 without disclosing a valuation or naming a lead investor.

Existing backers Asia Investment Capital, Granite Asia and Sinovation Ventures put in more money. CMB International joined as a new investor. The absence of a disclosed valuation is notable; investors are funding growth without publishing a price tag, and the company offered no revenue figures either.

How much has the company raised in total?

SiliconANGLE puts MegaRobo's total funding at about $600 million. That figure, not the company's own disclosure, includes a Series C of nearly $300 million raised in 2022. The company was founded in 2016. MegaRobo said the new money will fund three things:

  • Core technology development
  • Overseas expansion of its AI for Science business
  • Systems that let AI operate in more complex physical settings

The company has delivered products to more than 500 customers, it says. It did not name any of them. Its Megalaxy Lab service has served more than 200 customers, again without names. Both figures are company claims; no independent verification exists in the announcement.

What does the product lineup look like?

MegaRobo sells lab automation to drug makers, biotech companies and research institutions. The workflow covers stages from target discovery through drug screening and candidate optimization. Its hardware products include:

  • CellVue T2000, an automated cell-imaging instrument
  • Auflo, a sample-preparation workstation
  • Seloris, a cell-culture system

A software layer called One Intelligence Stack links models and agents to instruments, robots and the data they produce. That connection between AI planning and physical execution is the core pitch.

How do AI agents use the labs?

Through Megalaxy Lab, researchers or AI agents configure an experiment, send it to automated lab systems, track its progress and receive machine-readable results for the next round of design. The loop matters more than any single instrument; the architecture treats the lab as an endpoint that software can call.

The company has also launched Poreva Open with Tencent Cloud and Twist Bioscience, a protein design challenge in which Megalaxy Lab will test more than 10,000 submitted sequences in its wet labs. That number is concrete. It is also a marketing exercise as much as a scientific one.

What did the founder say?

"The first generation of AI learned from humanity's accumulated knowledge. The next generation will increasingly learn by acting in the physical world," said founder and chief executive Daniel Huang. The claim is ambitious. The company says the same architecture is meant for manufacturing and other physical systems, and SiliconANGLE noted it also sells precision measurement and inspection tools to manufacturers.

What is not said

The announcement lacks a valuation, a lead investor and named customers. It also lacks any figure for wet-lab throughput, installed systems or recurring revenue. Sovereign money from Oman, alongside Chinese investors such as Sinovation Ventures and CMB International, signals geographic diversification of the cap table at a time when Chinese deep-tech firms face tighter Western funding channels — though the company itself framed the round purely around technology and expansion.

MegaRobo now has the capital to push its automated-lab architecture into more physical domains, and its competitive position will hinge on whether Megalaxy Lab's closed design-test loop delivers results that named pharmaceutical customers are willing to confirm.

mlq.ai (Source)

Filed under

Share this article:

More from Sophie Lindqvist

Sophie Lindqvist

Show full bio

News editor covering money, funding and market shifts around Semiconductors, chip manufacturing, hardware, AI compute at Chip Dispatch.

1,178 articles

Read also

« Previous articleNext article »